Lipid nanoparticles for cancer therapy: State of the art and future prospects

Expert Opinion on Drug Delivery

Volumn 9, Issue 10, 2012, Pages 1245-1261

  Lasa Saracibar, Beatriz ^a   Estella Hermoso De Mendoza, Ander ^a   Guada, Melissa ^a   Dios Vieitez, Carmen ^a   Blanco Prieto, María J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Anticancer therapy; Lipid nanoparticles; Nanomedicine; Nanotechnology; Tumor targeting

Indexed keywords

ALPHA TOCOTRIENOL; AMPHOTERICIN B LIPID COMPLEX; BERACTANT; CAMPTOTHECIN; CAPECITABINE; CHLORAMBUCIL; CISPLATIN; CURCUMIN; DIAZEPAM; DOCETAXEL; DOXORUBICIN; ECONAZOLE; EDELFOSINE; ETOMIDATE; ETOPOSIDE; FLUOROURACIL; GADOLINIUM; IDARUBICIN; METHOTREXATE; MITOXANTRONE; NAVELBINE; PACLITAXEL; RESVERATROL; RETINOIC ACID; SIMVASTATIN; SOLID LIPID NANOPARTICLE; TAMOXIFEN CITRATE; TRIPENTONE 3 (3 HYDROXY 4 METHOXYPHENYL) 8H THIENO[2,3 B]PYRROLIZIN 8 ONE; UBIQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER THERAPY; COLON CANCER; COLORECTAL CANCER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG TARGETING; HUMAN; LUNG CANCER; LYMPHATIC SYSTEM; MICROEMULSION; NANOTECHNOLOGY; NONHUMAN; OVARY CANCER; PHYSICAL CHEMISTRY; REVIEW; SCALE UP;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; NANOPARTICLES; NEOPLASMS;

EID: 84866850021     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.717928     Document Type: Review

References (147)

1. WHO: Cancer. 2012. Available from: http://www.who.int/mediacentre/ factsheets/fs297/en/[Last accessed 15 May 2012]
2. Bhosle J, Hall G. Principles of cancer treatment by chemotherapy. Surgery 2009;27:173-7
3. Principe P, Braquet P. Advances in ether phospholipids treatment of cancer. Crit Rev Oncol 1995;18:155-78
4. Banna GL, Collovà E, Gebbia V, et al. Anticancer oral therapy: emerging related issues. Cancer Treat Rev 2010; 36:595-605
5. Estella-Hermoso de Mendoza A, Campanero MA, Mollinedo F, et al. Lipid nanomedicines for anticancer drug therapy. J Biomed Nanotechnol 2009; 5:323-43
6. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751-60
7. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011; 63:131-5
8. Paliwal R, Rai S, Vaidya B, et al. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine 2009;5:184-91
9. Estella-Hermoso de Mendoza A, Campanero MA, Lana H, et al. Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles. Nanomedicine 2012;7:679-90
10. Estella-Hermoso de Mendoza A, Preat V, Mollinedo F, et al. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J Control Release 2011156:421-6
11. Altmayer P, Grundmann U, Ziehmer M, et al. Comparative effectiveness and tolerance study of a new galenic etomidate formula. Anasthesiol Intensivmed Notfallmed Schmerzther 1993;28:415-19
12. Müller RH, Petersen RD, Hommoss A, et al. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 2007;59:522-30
13. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 1994;15:215-20
14. Speiser P. Lipid nanopellets als tragersystem fur arzneimittel zur peroralen anwendung. EP0167825; 1990
15. Eldem T, Speiser P, Hincal A. Optimization of spray-dried and-congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharm Res 1991;8:47-54
16. Schwarz C, Mehnert W, Lucks JS, et al. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release 1994;30:83-96
17. Müller RH, Lucks JS. Medication vehicles made of solid lipid particles (solid lipid nanospheres-SLN). EP0605497; 1993
18. Gasco MR. Solid lipid nanospheres from warm microemulsions. Pharm Tech Eur 1997;9:52-8
19. Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution. US188837; 1993
20. Cai S, Yang Q, Bagby TR, et al. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev 2011;63:901-908
21. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002;242:121-8
22. Liu D, Liu Z, Wang L, et al. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces 2011;85:262-9
23. Sharma P, Dube B, Sawant K. Development and evaluation of nanostructured lipid carriers of cytarabine for treatment of meningeal leukemia. J Nanosci Nanotechnol 2011;11:6676-82
24. Zhao X, Zhao Y, Geng L, et al. Pharmacokinetics and tissue distribution of docetaxel by liquid chromatography-mass spectrometry: evaluation of folate receptor-targeting amphiphilic copolymer modified nanostructured lipid carrier. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:3721-7
25. Li F, Weng Y, Wang L, et al. The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers. Int J Pharm 2010; 393:203-11
26. Zhang XG, Miao J, Dai YQ, et al. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int J Pharm 2008;361:239-44
27. Müller RH, Olbrich C. Lipid matrix-drug conjugates particle for controlled release of active ingredients. US6770299; 2002
28. Muchow M, Maincent P, Müller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 2008;34:1394-405
29. üMller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002;54(Suppl 1):S131-55
30. Avestin. Available from: www.avestin. com [Last accessed 15 May 2012]
31. APV. Available from: www.apv.com [Last accessed 15 May 2012]
32. Mader K. Solid lipid nanoparticles as drug carriers. In: Torchilin V, editor. Nanoparticulates as drug carriers. Imperial College Press; London, UK 2006
33. Charman WN, Stella VJ. Lymphatic transport of drugs. CRC Press; Boca Raton, Florida 1992
34. Zimmermann E, Müller RH, Mader K. Influence of different parameters on reconstitution of lyophilized SLN. Int J Pharm 2000;196:211-13
35. Brown SC, Palazuelos M, Sharma P, et al. Nanoparticle characterization for cancer nanotechnology and other biological applications. Methods Mol Biol 2010;624:39-65
36. Estella-Hermoso de Mendoza A, Rayo M, Mollinedo F, et al. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: development and in vitro characterization. Eur J Pharm Biopharm 2008;68:207-13
37. Patel MR, San Martin-Gonzalez MF. Characterization of ergocalciferol loaded solid lipid nanoparticles. J Food Sci 2012;77:N8-13
38. Zaucha M, Adamczyk Z, Barbasz J. Zeta potential of particle bilayers on mica: a streaming potential study. J Colloid Interface Sci 2011;360:195-203
39. Thielbeer F, Donaldson K, Bradley M. Zeta potential mediated reaction monitoring on nano and microparticles. Bioconjug Chem 2011;22:144-50
40. Freire JM, Domingues MM, Matos J, et al. Using zeta-potential measurements to quantify peptide partition to lipid membranes. Eur Biophys J 2011;40:481-7
41. Freitas C, Müller RH. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticles (SLN) dispersion. Int J Pharm 1998;168:221-9
42. Souto EB, Mehnert W, Müller RH. Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC. J Microencapsul 2006;23:417-33
43. Bunjes H, Koch MH. Saturated phospholipids promote crystallization but slow down polymorphic transitions in triglyceride nanoparticles. J Control Release 2005;107:229-43
44. Bunjes H, Koch MH, Westesen K. Effect of surfactants on the crystallization and polymorphism of lipid nanoparticles. Prog Colloid Polym Sci 2002;121:7-10
45. Bunjes H, Koch MH, Westesen K. Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J Pharm Sci 2003;92:1509-20
46. Bunjes H, Steiniger F, Richter W. Visualizing the structure of triglyceride nanoparticles in different crystal modifications. Langmuir 2007;23:4005-11
47. Kramer T, Kremer DM, Pikal MJ, et al. A procedure to optimize scale-up for the primary drying phase of lyophilization. J Pharm Sci 2009;98:307-18
48. Yadava P, Gibbs M, Castro C, et al. Effect of lyophilization and freeze-thawing on the stability of siRNA-liposome complexes. AAPS Pharm Sci Tech 2008;9:335-41
49. Bensouda Y, Laatiris A. The lyophilization of dispersed systems: influence of freezing process, freezing time, freezing temperature and RBCs concentration on RBCs hemolysis. Drug Dev Ind Pharm 2006;32:941-5
50. Seetharam R, Wada Y, Ramachandran S, et al. Long-term storage of bionanodevices by freezing and lyophilization. Lab Chip 2006;6:1239-42
51. Cavalli R, Caputo O, Gasco MR. Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur J Pharm Sci 2000;10:305-9
52. Souza LG, Silva EJ, Martins AL, et al. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur J Pharm Biopharm 2011;79:189-96
53. Subedi RK, Kang KW, Choi HK. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J Pharm Sci 2009;37:508-13
54. del Pozo-Rodriguez A, Solinis MA, Gascon AR, et al. Short-and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy. Eur J Pharm Biopharm 2009;71:181-9
55. zur Muhlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 1998;45:149-55
56. Battaglia L, Gallarate M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv 2012;9:497-508
57. Wu L, Tang C, Yin C. Folate-mediated solid-liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol). Drug Dev Ind Pharm 2010;36:439-48
58. Jain A, Agarwal A, Majumder S, et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release 2010;148:359-67
59. Kuo YC, Liang CT. Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells. Colloids Surf B Biointerfaces 2011;85:131-7
60. Huang ZR, Hua SC, Yang YL, et al. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol Sin 2008;29:1094-102
61. Aji Alex MR, Chacko AJ, Jose S, et al. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci 2011;42:11-18
62. Dong X, Mattingly CA, Tseng MT, et al. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res 2009;69:3918-26
63. Xu Z, Chen L, Gu W, et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 2009;30:226-32
64. Ying XY, Du YZ, Hong LH, et al. Magnetic lipid nanoparticles loading doxorubicin for intracellular delivery: preparation and characteristics. J Magn Magn Mater 2011;323:1088-93
65. Mulik RS, Monkkonen J, Juvonen RO, et al. Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int J Pharm 2010;398:190-203
66. Yang X, Koh CG, Liu S, et al. Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against bcl-2. Mol Pharm 2009;6:221-30
67. Gupta Y, Jain A, Jain SK. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Pharm Pharmacol 2007;59:935-40
68. Jain SK, Chaurasiya A, Gupta Y, et al. Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting. J Microencapsul 2008;25:289-97
69. Nimje N, Agarwal A, Saraogi GK, et al. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J Drug Target 2009;17:777-87
70. Mizrahy S, Raz SR, Hasgaard M, et al. Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. J Control Release 2011;156:231-8
71. Rivkin I, Cohen K, Koffler J, et al. Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials 2010;31:7106-14
72. Scheibner KA, Lutz MA, Boodoo S, et al. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 2006;177:1272-81
73. Liu Z, Zhong Z, Peng G, et al. Folate receptor mediated intracellular gene delivery using the charge changing solid lipid nanoparticles. Drug Deliv 2009; 16:341-7
74. Schroeder JE, Shweky I, Shmeeda H, et al. Folate-mediated tumor cell uptake of quantum dots entrapped in lipid nanoparticles. J Control Release 2007;124:28-34
75. Goutayer M, Dufort S, Josserand V, et al. Tumor targeting of functionalized lipid nanoparticles: assessment by in vivo fluorescence imaging. Eur J Pharm Biopharm 2010;75:137-47
76. Shimon-Hophy M, Wadhwani KC, Chandrasekaran K, et al. Regional blood-brain barrier transport of cationized bovine serum albumin in awake rats. Am J Physiol 1991; 261:R478-83
77. Wadhwani KC, Shimon-Hophy M, Rapoport SI. Enhanced permeabilities of cationized-bovine serum albumins at the blood-nerve and blood-brain barriers in awake rats. J Neurosci Res 1992; 32:407-14
78. Agarwal A, Agrawal H, Tiwari S, et al. Cationic ligand appended nanoconstructs: a prospective strategy for brain targeting. Int J Pharm 2011;421:189-201
79. Hsu MH, Su YC. Iron-oxide embedded solid lipid nanoparticles for magnetically controlled heating and drug delivery. Biomed Microdevices 2008;6:785-93
80. Bareschino MA, Schettino C, Rossi A, et al. Treatment of advanced non small cell lung cancer. J Thorac Dis 2011; 3:122-33
81. National cancer institute; general information about non-small cell lung cancer treatment. 2012. Available from: http://www.cancer.gov/cancertopics/pdq/ treatment/non-smallcell-lung/healthprofessional [Last accessed 14 May 2012]
82. Shi SJ, Zhong ZR, Liu J, et al. Solid lipid nanoparticles loaded with anti-microRNA oligonucleotides (AMOs) for suppression of MicroRNA-21 functions in human lung cancer cells. Pharm Res 2012;29:97-109
83. Wan F, You J, Sun Y, et al. Studies on PEG-modified SLNs loading vinorelbine bitartrate (I): preparation and evaluation in vitro. Int J Pharm 2008;359:104-10
84. You J, Wan F, de Cui F, et al. Preparation and characteristic of vinorelbine bitartrate-loaded solid lipid nanoparticles. Int J Pharm 2007; 343:270-6
85. Amoozgar Z, Yeo Y. Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012; 4:219-33
86. National cancer institute; general information about colon cancer. 2012.Available from: http://www.cancer.gov/cancertopics/pdq/treatment/colon/ HealthProfessional/page1 [Last accessed 14 May 2012]
87. Yassin AE, Anwer MK, Mowafy HA, et al. Optimization of 5-flurouracil solidlipid nanoparticles: a preliminary study to treat colon cancer. Int J Med Sci 2010;7:398-408
88. Minelli R, Serpe L, Pettazzoni P, et al. Cholesteryl butyrate solid lipid nanoparticles inhibit the adhesion and migration of colon cancer cells. Br J Pharmacol 2011;166:587-601
89. American cancer society; breast cancer. 2012.Available from: http://www.cancer.org/Cancer/BreastCancer/DetailedGuide/breast-cancer-treating- general-info [Last accessed 14 May 2012]
90. Lu B, Xiong SB, Yang H, et al. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases. Eur J Pharm Sci 2006;28:86-95
91. Reddy LH, Vivek K, Bakshi N, et al. Tamoxifen citrate loaded solid lipid nanoparticles (SLN): preparation, characterization, in vitro drug release, and pharmacokinetic evaluation. Pharm Dev Technol 2006;11:167-77
92. Zhigaltsev IV, Winters G, Srinivasulu M, et al. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. J Control Release 2010;144:332-40
93. Gong X, Moghaddam MJ, Sagnella SM, et al. Lamellar crystalline self-assembly behaviour and solid lipid nanoparticles of a palmityl prodrug analogue of capecitabine-a chemotherapy agent. Colloids Surf B Biointerfaces 2011;85:349-59
94. Hrycushko BA, Gutierrez AN, Goins B, et al. Radiobiological characterization of post-lumpectomy focal brachytherapy with lipid nanoparticle-carried radionuclides. Phys Med Biol 2011;56:703-19
95. Alvarez P, Marchal JA, Boulaiz H, et al. 5-fluorouracil derivatives: a patent review. Expert Opin Ther Pat 2012;22:107-23
96. Venishetty VK, Komuravelli R, Kuncha M, et al. Increased brain uptake of docetaxel and ketoconazole loaded folate grafted solid lipid nanoparticles. Nanomedicine 2012; In press
97. Kuo YC, Liang CT. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials 2011;32:3340-50
98. Brioschi A, Zara GP, Calderoni S, et al. Cholesterylbutyrate solid lipid nanoparticles as a butyric acid prodrug. Molecules 2008;13:230-54
99. Goppert TM, Müller RH. Plasma protein adsorption of Tween 80-and poloxamer 188-stabilized solid lipid nanoparticles. J Drug Target 2003;11:225-31
100. Mollinedo F, de la Iglesia-Vicente J, Gajate C, et al. In vitro and in vivo selective antitumor activity of edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin Cancer Res 2010;16:2046-54
101. Estella-Hermoso de Mendoza A, Campanero MA, de la Iglesia-Vicente J, et al. Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice. Clin Cancer Res 2009;15:858-64
102. American cancer society: Ovarian cancer. 2010.Available from: http://www.cancer.org/Cancer/OvarianCancer/DetailedGuide/ovarian-cancer [Last accessed 20 May 2012]
103. Siddiqui A, Patwardhan GA, Liu YY, et al. Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells. Int J Pharm 2010;400:251-9
104. Zhang P, Chen L, Zhang Z, et al. Pharmacokinetics in rats and efficacy in murine ovarian cancer model for solid lipid nanoparticles loading docetaxel. J Nanosci Nanotechnol 2010;10:7541-4
105. Lee MK, Lim SJ, Kim CK. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 2007;28:2137-46
106. Sanjula B, Shah FM, Javed A, et al. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J Drug Target 2009;17:249-56
107. Reddy LH, Adhikari JS, Dwarakanath BS, et al. Tumoricidal effects of etoposide incorporated into solid lipid nanoparticles after intraperitoneal administration in Dalton's lymphoma bearing mice. AAPS J 2006;8:E254-62
108. Ma P, Dong X, Swadley CL, et al. Development of idarubicin and doxorubicin solid lipid nanoparti cles to overcome pgp-mediated multiple drug resistance in leukemia. J Biomed Nanotechnol 2009;5:151-61
109. Pan X, Chen L, Liu S, et al. Antitumor activity of G3139 lipid nanoparticles (LNPs). Mol Pharm 2009;6:211-20
110. Bauman JA, Li SD, Yang A, et al. Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res 2010;38:8348-56
111. de Jesus MB, Ferreira CV, de Paula E, et al. Design of solid lipid nanoparticles for gene delivery into prostate cancer. J Control Release 2010;148:e89-90
112. French JT, Goins B, Saenz M, et al. Interventional therapy of head and neck cancer with lipid nanoparticle-carried rhenium 186 radionuclide. J Vasc Interv Radiol 2010;21:1271-9
113. Holpuch AS, Hummel GJ, Tong M, et al. Nanoparticles for local drug delivery to the oral mucosa: proof of principle studies. Pharm Res 2010;27:1224-36
114. Kohane DS, Langer R. Biocompatibility and drug delivery systems. Chem Sci 2010;1:441-6
115. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 2009;71:161-72
116. Severino P, Andreani T, Macedo AS, et al. Current state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J Drug Deliv 2012;2012:750891
117. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007;59:478-90
118. Fangueiro JF, Gonzalez-Mira E, Martins-Lopes P, et al. A novel lipid nanocarrier for insulin delivery: production, characterization and. toxicity testing. Pharm Dev Technol 2011; published online 28 June 2011 p. 12
119. Liu J, Gong T, Fu H, et al. Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm 2008;356:333-44
120. Rawat MK, Jain A, Singh S. In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats. J Pharm Sci 2011;6:2406-7
121. üWissing SA, Kayser O, Mller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257-72
122. Smijs TG, Bouwstra JA. Focus on skin as a possible port of entry for solid nanoparticles and the toxicological impact. J Biomed Nanotechnol 2010;6:469-84
123. Spada G, Gavini E, Cossu M, et al. Solid lipid nanoparticles with and without hydroxypropyl-beta-cyclodextrin: A comparative study of nanoparticles designed for colonic drug delivery. Nanotechnol 2012; published on line 6 Feb 2012; doi: doi:10.1088/0957-4484/23/9/095101
124. Estella-Hermoso de Mendoza A, Calvo P, Bishop A, et al. Comparison of pharmacokinetic profiles of PM02734 loaded lipid nanoparticles and cyclodextrins: in vitro and in vivo characterization. J Biomed Nanotechnol 2012;8:723-8
125. Feng L, Wu H, Ma P, et al. Development and optimization of oil-filled lipid nanoparticles containing docetaxel conjugates designed to control the drug release rate in vitro and in vivo. Int J Nanomedicine 2011;6:2545-56
126. Lim S, Lee M, Kim C. Altered chemical and biological activities of all-trans retinoic acid incorporated in solid lipid nanoparticle powders. J Control Release 2004;100:53-61
127. Song H, Nie S, Yang X, et al. Characterization and in vivo evaluation of novel lipid-chlorambucil nanospheres prepared using a mixture of emulsifiers for parenteral administration. Int J Nanomedicine 2010;5:933-42
128. Wang L, Liu Z, Liu D, et al. Docetaxelloaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity. Int J Pharm 2011;413:194-201
129. Piao H, Ouyang M, Xia D, et al. In vitro-in vivo study of CoQ10-loaded lipid nanoparticles in comparison with nanocrystals. Int J Pharm 2011;419:255-9
130. Teskac K, Kristl J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm 2010; 390:61-9
131. Lee P, Zhang R, Li V, et al. Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation. Int J Nanomedicine 2012;7:731-7
132. Dong X, Mattingly CA, Tseng M, et al. Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization. Eur J Pharm Biopharm 2009;72:9-17
133. Oyewumi MO, Mumper RJ. Gadolinium-loaded nanoparticles engineered from microemulsion templates. Drug Dev Ind Pharm 2002;28:317-28
134. Gallarate M, Trotta M, Battaglia L, et al. Cisplatin-loaded SLN produced by coacervation technique. J Drug Deliv Sci Tech 2010;20:343-7
135. Chirio D, Gallarate M, Peira E, et al. Formulation of curcumin-loaded solid lipid nanoparticles produced by fatty acids coacervation technique. J Microencapsul 2011;28:537-48
136. Battaglia L, Serpe L, Muntoni E, et al. Methotrexate-loaded SLNs prepared by coacervation technique: in vitro cytotoxicity and in vivo pharmacokinetics and biodistribution. Nanomedicine 2011;6:1561-73
137. Lamprecht A, Benoit J. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J Control Release 2006;112:208-13
138. Malzert-Fréon A, Vrignaud S, Saulnier P, et al. Formulation of sustained release nanoparticles loaded with a tripentone, a new anticancer agent. Int J Pharm 2006;320:157-64
139. Lacoeuille F, Hindre F, Moal F, et al. In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel. Int J Pharm 2007;344:143-9
140. Yu YH, Kim E, Park DE, et al. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur J Pharm Biopharm 2012;80:268-73
141. Tian J, Pang X, Yu K, et al. Preparation, characterization and in vivo distribution of solid lipid nanoparticles loaded with cisplatin. Pharmazie 2008;63:593-7
142. Ali H, Shirode AB, Sylvester PW, et al. Preparation, characterization, and anticancer effects of simvastatintocotrienol lipid nanoparticles. Int J Pharm 2010;389:223-31
143. Das S, Ng WK, Kanaujia P, et al. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf B Biointerfaces 2011;88:483-9
144. Videira M, Almeida AJ, Fabra A. Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect. Nanomedicine 2011; published on line 27 December 2011; doi: 10.1016/j.nano.2011.12.007
145. Abuasal BS, Lucas C, Peyton B, et al. Enhancement of intestinal permeability utilizing solid lipid nanoparticles increases gamma-tocotrienol oral bioavailability. Lipids 2012;47:461-9
146. Pandita D, Ahuja A, Velpandian T, et al. Characterization and in vitro assessment of paclitaxel loaded lipid nanoparticles formulated using modified solvent injection technique. Pharmazie 2009;64:301-10
147. Wang T, Wang N, Zhang Y, et al. Solvent injection-lyophilization of tert-butyl alcohol/water cosolvent systems for the preparation of drug-loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces 2010;79:254-61